Young Yang

Prof. Young Yang

Sookmyung Women's University
+1
orcid

Research Focus & Metrics

Academic Career Length

31Years (1996-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 June 2000 in The Journal of Immunology
Verified
Journal Article
Closed access
PDF file
EJEunsung Junn
Eunsung Junn
SHSeung Hyun Han
Seung Hyun Han
JIJoo Young Im
Joo Young Im
YYYoung Yang
Young Yang
ECEun Wie Cho
Eun Wie Cho
ICInpyo Choi
Inpyo Choi
As a result of identifying the regulatory proteins of thioredoxin (TRX), a murine homologue for human vitamin D3 up-regulated protein 1 (VDUP1) was identified from a yeast two-hybrid screen. Cotransfection into 293 cells and precipitation assays confirmed that mouse VDUP1 (mVDUP1) bound to TRX, but it failed to bind to a Cys32 and Cys35 mutant TRX, suggesting the redox-active site is critical for binding. mVDUP1 was ubiquitously expressed in various tissues and located in the cytoplasm. Biochemical analysis showed that mVDUP1 inhibited the insulin-reducing activity of TRX. When cells were treated with various stress stimuli such as H2O2 and heat shock, mVDUP1 was significantly induced. TRX is known to interact with other proteins such as proliferation-associated gene and apoptosis signal-regulating kinase 1. Coexpression of mVDUP1 interfered with the interaction between TRX and proliferation-associated gene or TRX and ASK-1, suggesting its roles in cell proliferation and oxidative stress. To investigate the roles of mVDUP1 in oxidative stress, mVDUP1 was overexpressed in NIH 3T3 cells. When cells were exposed to stress, cell proliferation was declined with elevated apoptotic cell death compared with control cells. In addition, c-Jun N-terminal kinase activation and IL-6 expression were elevated. Taken together, these results demonstrate that mVDUP1 functions as an oxidative stress mediator by inhibiting TRX activity.

Verified
Journal Article
Open access
PDF file
JNJi-Yoon Noh
Ji-Yoon Noh
YYYoung Yang
Young Yang
Haiyoung JungHaiyoung Jung
Haiyoung Jung
Osteoporosis is the most common chronic metabolic bone disease. It has been estimated that more than 10 million people in the United States and 200 million men and women worldwide have osteoporosis. Given that the aging population is rapidly increasing in many countries, osteoporosis could become a global challenge with an impact on the quality of life of the affected individuals. Osteoporosis can be defined as a condition characterized by low bone density and increased risk of fractures due to the deterioration of the bone architecture. Thus, the major goal of treatment is to reduce the risk for fractures. There are several treatment options, mostly medications that can control disease progression in risk groups, such as postmenopausal women and elderly men. Recent studies on the basic molecular mechanisms and clinical implications of osteoporosis have identified novel therapeutic targets. Emerging therapies targeting novel disease mechanisms could provide powerful approaches for osteoporosis management in the future. Here, we review the etiology of osteoporosis and the molecular mechanism of bone remodeling, present current pharmacological options, and discuss emerging therapies targeting novel mechanisms, investigational treatments, and new promising therapeutic approaches.

24 June 2003 in Oncogene
Verified
Journal Article
Open access
PDF file
SHSeung Hyun Han
Seung Hyun Han
JJJun Ho Jeon
Jun Ho Jeon
HJHyang Ran Ju
Hyang Ran Ju
UJUhee Jung
Uhee Jung
KKKun Young Kim
Kun Young Kim
ICInpyo Choi
Inpyo Choi
Vitamin D3 upregulated protein 1 (VDUP1) is a 1,25-dihydroxyvitamin D3 (1,25(OH)2D3) upregulated protein, and it is induced by various stresses. In human tumor tissues, VDUP1 expression was downregulated. Upon stimulation by growth-inhibitory signals such as TGF-β1 and 1,25(OH)2D3, its expression was rapidly upregulated as the cell growth was retarded. The transfection of VDUP1 in tumor cells reduced cell growth. The VDUP1 expression was also increased when the cell-cycle progression was arrested. Transfection of VDUP1 induced cell-cycle arrest at the G0/G1 phase, indicating that VDUP1 possesses a tumor-suppressive activity. In addition, it was found that VDUP1 interacted with promyelocytic leukemia zinc-finger, Fanconi anemia zinc-finger, and histone deacetylase 1, which are known to be transcriptional corepressors. VDUP1 itself suppressed IL-3 receptor and cyclin A2 promoter activity. Taken together, these results suggest that VDUP1 is a novel antitumor gene which forms a transcriptional repressor complex.

1 February 2012 in Biochemical Pharmacology
Verified
Journal Article
Closed access
HKHak-Su Kim
Hak-Su Kim
MKMyung-Jin Kim
Myung-Jin Kim
EKEun Ju Kim
Eun Ju Kim
YYYoung Yang
Young Yang
MLMyeong-Sok Lee
Myeong-Sok Lee
Jong-Seok LimJong-Seok Lim
Jong-Seok Lim

2 January 2008 in The FASEB Journal
Verified
Journal Article
Closed access
JJJun Ho Jeon
Jun Ho Jeon
KKKun‐Yong Kim
Kun‐Yong Kim
JKJae Hyeong Kim
Jae Hyeong Kim
ABAhmi Baek
Ahmi Baek
HCHyungin Cho
Hyungin Cho
YYYoung Yang
Young Yang

1 January 2010 in Molecular Cancer
Verified
Journal Article
Open access
PDF file
JLJaehyouk Lee
Jaehyouk Lee
DJDong-Jun Jeong
Dong-Jun Jeong
JKJinsun Kim
Jinsun Kim
SLSoonduck Lee
Soonduck Lee
JPJin-Hwa Park
Jin-Hwa Park
MLMyeong-Sok Lee
Myeong-Sok Lee
Klotho was originally characterized as an anti-aging gene that predisposed Klotho-deficient mice to a premature aging-like syndrome. Recently, KLOTHO was reported to function as a secreted Wnt antagonist and as a tumor suppressor. Epigenetic gene silencing of secreted Wnt antagonists is considered a common event in a wide range of human malignancies. Abnormal activation of the canonical Wnt pathway due to epigenetic deregulation of Wnt antagonists is thought to play a crucial role in cervical tumorigenesis. In this study, we examined epigenetic silencing of KLOTHO in human cervical carcinoma.